Xylazine

Brand Names: Xylazine is not approved for human use in Jordan and does not have registered pharmaceutical brand names for human medicine. In veterinary practice in Jordan, it may be available under generic names like 'Xylazine' or possibly under veterinary-specific brands, but no specific Jordanian trade names for human use are documented.

Drug Class: Alpha-2 adrenergic agonist

Overview

Xylazine is an alpha-2 adrenergic agonist primarily used in veterinary medicine as a sedative, analgesic, and muscle relaxant. It is not approved for human use by the FDA but has emerged as an adulterant in illicit drugs, particularly opioids, leading to significant public health concerns due to its severe side effects and potential for overdose.

Mechanism of Action

Xylazine acts as an agonist at alpha-2 adrenergic receptors in the central and peripheral nervous systems, leading to inhibition of norepinephrine release. This results in sedation, analgesia, muscle relaxation, and decreased sympathetic outflow, similar to other alpha-2 agonists like clonidine, but with more potent sedative effects.

Indications

  • Veterinary use: Sedation, analgesia, and muscle relaxation in animals (e.g., horses, cattle, dogs, cats).
  • Not approved for human use. Illicitly used as an adulterant in drugs like heroin, fentanyl, or cocaine to enhance or prolong effects.

Dosage

For veterinary use only, dosage varies by animal species, weight, and procedure (e.g., 0.1–1.1 mg/kg intramuscularly or intravenously in animals). Not applicable for human use; any human exposure is accidental or illicit and requires emergency medical attention.

Contraindications

  • Hypersensitivity to xylazine.
  • Use in animals with cardiovascular disease, shock, or respiratory depression.
  • Not indicated for human use under any circumstances.

Side Effects

  • Sedation, drowsiness, dizziness.
  • Hypotension, bradycardia, arrhythmias.
  • Respiratory depression, apnea.
  • Hyperglycemia (due to inhibition of insulin secretion).
  • Dry mouth, nausea, vomiting.
  • Skin ulcers, abscesses, and tissue damage at injection sites.
  • Coma or death in overdose cases.

Interactions

  • Opioids (e.g., fentanyl, heroin): Potentiates respiratory depression and sedation, increasing overdose risk.
  • Other CNS depressants (e.g., alcohol, benzodiazepines): Enhances sedative effects.
  • Antihypertensives: May exacerbate hypotension.
  • Insulin or antidiabetic drugs: Alters glucose control due to hyperglycemic effect.